Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece

Introduction: Dihydropyrimidine dehydrogenase (DPD), encoded by DPYD gene, is the rate-limiting enzyme responsible for fluoropyrimidine (FP) catabolism. DPYD gene variants seriously affect DPD activity and are well validated predictors of FP-associated toxicity. DPYD variants rs3918290, rs55886062,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragia, Georgia, Maslarinou, Anthi, Atzemian, Natalia, Biziota, Eirini, Koukaki, Triantafyllia, Ioannou, Charalampia, Balgkouranidou, Ioanna, Kolios, George, Kakolyris, Stylianos, Xenidis, Nikolaos, Amarantidis, Kyriakos, Manolopoulos, Vangelis G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536177/
https://www.ncbi.nlm.nih.gov/pubmed/37781702
http://dx.doi.org/10.3389/fphar.2023.1248898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536177/
https://www.ncbi.nlm.nih.gov/pubmed/37781702
http://dx.doi.org/10.3389/fphar.2023.1248898

Ejemplares similares